Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Simple antibiotic may shield kidney patients from Post-Hospital infections

NCT ID NCT07224997

Prevention Sponsor: Hospital Civil de Guadalajara Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving a common antibiotic (TMP/SMX) to adults who recently had acute kidney injury can prevent infections after they leave the hospital. About 120 participants will receive either the antibiotic or a placebo for 90 days. The goal is to see if this approach reduces infections and related hospital visits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2025

An estimate. Start dates often move.

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Age ≥18 years. * Index hospitalization complicated by AKI (KDIGO criteria) prior to discharge. * Planned discharge to community/rehabilitation with capacity for follow-up. * Ability to provide informed consent. Exclusion Criteria: * Known allergy to sulfonamides or TMP/SMX. * Pregnancy or breastfeeding. * Severe hepatic disease (e.g., Child-Pugh C). * Severe cytopenia (e.g., ANC \<1.0×10⁹/L or platelets \<50×10⁹/L). * Baseline hyperkalemia (\>5.5 mmol/L) not correctable prior to randomization. * Concomitant medications with high-risk interactions not amenable to dose/monitoring (per protocol). * Current systemic antimicrobial therapy planned for \>14 days after discharge (prophylaxis not indicated). * Inability to adhere to study procedures or follow-up.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute kidney disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute kidney injury infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute kidney disease Acute kidney injuries Acute kidney injury (AKI)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.